Abstract: A method of detecting, diagnosing and prognosticating atherosclerosis by measuring the activities of ?6 and ?5 desaturases is described. It is suggested that enhancing the activities of ?6 and ?5 desaturases results in an increase in the plasma, leukocyte, platelet and endothelial cell levels of ?-linolenic, dihomo-?-linolenic, arachidonic, stearidonic, 20:4 ?-3, eicosapentaneoic and docosahexaenoic acids and PGE1 (prostaglandin E1), prostacyclin (PGI2), prostaglandin I3 (PGI3), lipoxins, resolvins, protectins, nitric oxide, and nitrolipids that prevent, arrest and reverse atherosclerosis. The invention is also directed to the delivery of proteins, peptides, lipids, lipoproteins, glycolipids, statins and troglitazones and their derivatives, and other compounds (synthetic or natural), cDNA clones and genes of ?6 and ?5 desaturases to enhance the activities of ?6 and ?5 desaturases in vivo to prevent, arrest, reverse and treat atherosclerosis.

Abstract: A method of preventing, arresting, reversing and treatment of atherosclerosis by enhancing the activities of ?6 and ?5 desaturases such that the cell, tissue, and plasma levels of various polyunsaturated fatty acids (PUFAs) and, in particular that of endothelial cells lining the blood vessels will increase. More particularly, the invention is directed to enhance the activities of ?6 and ?5 desaturases that, in turn, will lead to increased production of products of polyunsaturated fatty acids such as prostacyclin (PGI2), PGI3, lipoxins, resolvins, protecting, PGE1 (prostaglandin E1), nitric oxide, and nitrolipids such that atherosclerotic process will be prevented, arrested, reversed and this will lead to efficient arrest, regression, prevention and/or treatment of even established atherosclerosis and its associated conditions.

Abstract: A method of stabilizing and potentiating actions and administration of neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4, and nerve growth factor and their receptors by using in coupling conjugation with polyunsaturated fatty acids (PUFAs) in the prevention and/or treatment of obesity, type 2 diabetes mellitus, metabolic syndrome X, Alzheimer's disease, depression, Parkinson's disease, and schizophrenia is described. The invention is directed to the efficacious use of various neurotrophins by using them in combination with polyunsaturated fatty acids chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid, docosapentaenoic acid and conjugated linoleic acid in predetermined quantities.

Abstract: The present invention relates to a strategy or method of detecting, diagnosing, and prognosticating low-grade systemic inflammatory conditions such as insulin resistance, type 2 diabetes mellitus, hypertension, hyperlipidemias, and Alzheimer's disease; various cancers, and acute and chronic collagen vascular diseases including rheumatoid arthritis (RA), and lupus; proliferative diabetic retinopathy; macular degeneration; multiple sclerosis, psoriasis, chronic renal failure, end-stage renal disease, glomerulonephritis including minimal change nephropathy, proliferative glomerulonephritis, nephritis secondary to underlying systemic diseases using plasma and/or tissue levels of acetylcholinesterase and butyrylcholinesterase as a marker. The method employed to detect acetylcholinesterase and butyrylcholinesterase could include various methods such as but not limited to turbimetric test, or ELISA (enzyme linked immunosorbent assay), fluorometric, radioimmunoassay, and spectrophotometric methods.